Pomegranate use to attenuate bone loss in major musculoskeletal diseases: An evidence-based review

Current Drug Targets

Volumn 14, Issue 13, 2013, Pages 1565-1578

  Shuid, Ahmad Nazrun ^a   Mohamed, Isa Naina ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Osteoarthritis; Osteoporosis; Pomegranate; Rheumatoid arthritis

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; POMEGRANATE EXTRACT; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; BONE DENSITY CONSERVATION AGENT; PLANT EXTRACT;

ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; POMEGRANATE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; WESTERN BLOTTING; ANIMAL; ARTHRITIS, RHEUMATOID; BONE DENSITY; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; EVIDENCE BASED MEDICINE; LYTHRACEAE; PHYTOTHERAPY;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; HUMANS; OSTEOARTHRITIS; OSTEOPOROSIS; PHYTOTHERAPY; PLANT EXTRACTS; PUNICACEAE;

EID: 84889028717     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450114666131108155039     Document Type: Review

References (92)

1. World Health Organization, 2007: WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Summary Meeting Report. Brussels, Belgium, WHO Press, Geneva 5-7 May 2004.
2. International Osteoporosis Foundation: Facts and statistics about osteoporosis and its impact. International Osteoporosis Foundation. Journal of Bone and Mineral Research 2009 4:113-118, http://www.iofbonehealth.org/facts-andstatistics.html
3. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000; 133(8): 635-46.
4. Zeni JA, Axe MJ, Snyder-Mackler L. Clinical predictors of elective total joint replacement in persons with end-stage knee osteoarthritis. BMC Musculoskelet Disord 2010; 11: 86
5. Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995; 38(8): 1134-41
6. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum 2008; 59(9): 1207-13.
7. DeFrances C, Podgornik MN, 2004 National Hospital Discharge Survey. Adv Data 2006; 371: 1-19.
8. Gevers G, Dequeker J, Geusens P, Nyssen-Behets C, Dhem A. Physical and histomorphological characteristics of iliac crest bone differ according to the grade of osteoarthritis at the hand. Bone 1989; 10: 173-7
9. Sowers M, Zobel D, Weissfeld L, Hawthorne VM, Carman W. Progression of osteoarthritis of the hand and metacarpal bone loss. A twenty-year follow-up of incident cases. Arthritis Rheum 1991; 34: 36-42.
10. Seibel MJ, Duncan A, Robins SP. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 1989; 16: 964-70.
11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 Revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24
12. Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheum (Oxford) 2006; 45: 478-80.
13. Malahias M, Gardner H, Hindocha S, Juma A, Khan W. The Future of Rheumatoid Arthritis and Hand Surgery Combining Evolutionary Pharmacology and Surgical Technique. Open Orthop J 2012; 6: 88-94.
14. Larsen A, Dale K, Eek. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagnosis 1975; 16: 393
15. Goldring SR. Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 2003; 73(2): 97-100.
16. Nakayama H. Osteoporosis in the patients with rheumatoid arthritis: the efficacy and the selection of the osteoporosis therapeutic drug. Clin Calcium 2007; 17(10): 1607-12.
17. Shuid AN, Norazlina M, Norliza M, Ima Nirwana S. The Antiinflammatory Role of Vitamin E in Prevention of Osteoporosis. Adv Pharmacoll Sci 2012; 2012: 142702.
18. Nair SP, Williams RJ, Henderson B. Advances in our understanding of the bone and joint pathology caused by Staphylococcus aureus infection. Rheum(Oxford) 2000; 39(8): 821-34.
19. Srivastava S, Weitzmann MN, Cenci S, et al. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest 1999; 104(4): 503-13.
20. Eigler A, Endres S. Therapy with anti-TNF antibodies in patients with Crohn disease. Z Gastroenterol 1997; 35(9): 899-901
21. Li YP, Stashenko P. Proinflammatory cytokines tumor necrosis factor-alpha and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter. J Immunol 1992; 148(3): 788-94.
22. Taichman RS, Hauschka PV. Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflamm 1992; 16(6): 587-601
23. Kitajima I, Soejima Y, Takasaki I, et al. Ceramide-induced nuclear translocation of NF-kappa B is a potential mediator of the apoptotic response to TNF-alpha in murine clonal osteoblasts. Bone 1996; 19(3): 263-70.
24. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 1998; 13(5): 793-802.
25. Gilbert L, He X, Farmer P, Boden S, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141(11): 3956-64.
26. Kaneki H, Guo R, Chen D, et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 2006; 281(7): 4326-33.
27. Bown D. Encyclopaedia of Herbs and Their Uses. London: Dorling Kindersley 1995.
28. Palaniswamy R. A guide to medicinal plants of Asian origin and culture. Newbury, UK: CPL Press; 2003.
29. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agr Food Chem 2000; 48: 4581-9.
30. Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic apolipoprotein E-deficient mice. Am J Clin Nutr 2000; 71(5): 1062-76.
31. Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 2001; 158: 195-8.
32. Kaplan M, Hayek T, Raz A, et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular chlesterol accumulation and development of atherosclerosis. J Nutr 2001; 131: 2082-9.
33. Halvorsen BL, Holte K, Myhrstad MCW, et al. A systematic screening of total antioxidants in dietary plants. J Nutr 2002; 132: 461-71.
34. Noda Y, Kaneyuki T, Mori A, Packe L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: Delphinidin, cyaniding, and pelargonidin. J Agr Food Chem 2002; 50: 166-71
35. Singh RP, Murthy KNC, Jayaprakasha GK. Studies on the antioxidant activity of pomegranate (Punica granatum) peel and seed extract using in vitro models. J Agr Food Chem 2002; 50: 81-6
36. Jurenka J. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 2008; 13: 128-44.
37. Moneam NMA, Sharasky AS, Badreldin MM. Oestrogen content of pomegranate seeds. J Chromatogr 1988; 438: 438-42.
38. Heftmann E, Ko ST, Bennett RD. Identification of estrone in pomegranate seeds. Phytochem 1966; 5: 1337-9.
39. Sharaf A, Nigm SAR. The oestrogenic activity of pomegranate seed oil. J Endocrinol 1964; 29: 91-2.
40. Sun JS, Li YY, Liu M, Sheu SY. Effects of coumestrol on neonatal and adult mice osteoblasts activities. J Biomed Mat Res 2007; 81: 214-23.
41. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 2001; 24: 351-6
42. Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 2003; 78: 593-609
43. Mardon J, Mathey J, Kati-Coulibaly S, et al. Influence of lifelong soy isoflavones consumption on bone mass in the rat. Exp Biol Med 2008; 233: 229-37
44. Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H, Yoshimora H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J Ethnopharm 2004; 92: 93-101.
45. Rossouw J, Anderson G, Prentice R. Risks and benefits of estrogen plus progestin in postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-33
46. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. J Am Med Assoc 2003; 289: 3243-53.
47. Kim ND, Mehta B, Yu W, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002; 71: 203-17
48. de Nigris F, Williams-Ignarro S, Sica V, et al. Effects of a pomegranate fruit extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis. Cardio Res 2007; 73: 414-23.
49. Esmaillzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia. Int J Vit Nutr Res 2006; 76: 147-51.
50. Rosenblat M, Hayek T, Aviram M. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis 2006;187: 363-71.
51. Seeram NP, Adams LS, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005; 16: 360-7.
52. Afaq F, Saleem M, Krueger CG, Reed JD, Mukhtar H. Anthocyaninand hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer 2005; 113: 423-33.
53. Ahmed S, Wang N, Hafeez BB, Cheruvu VK, Haqqi TM. Punica granatum L. extract inhibits IL-1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappaB in human chondrocytes in vitro. J Nutr 2005; 135: 2096-102.
54. Hayden MS, Ghosh S. Signaling to NFB. Genes Devt 2004; 18: 2195-24.
55. Schieven GS. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem. 2005; 5: 921-8.
56. Gilbert L, He X, Farmer P, et al. Expression of the Osteoblast Differentiation Factor RUNX2 (Cbfa1/AML3/Pebp2 A) Is Inhibited by Tumor Necrosis Factor-. J Biol Chem 2002; 277: 2695-701
57. Abbas S, Zhang Y H, Clohisy J C, Abu-Amer Y. Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type 1 receptor. Cytokine 2003; 22: 33-41
58. Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol 2005; 288: E1011-E1018
59. Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM. Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutr 2008; 24: 733-43.
60. Hadipour-Jahromy M, Mozaffari-Kermani R. Chondroprotective effects of pomegranate juice on monoiodoacetate-induced osteoarthritis of the knee joint of mice. Phytother Res 2010; 24: 182-5.
61. Kim YH, Choi EM. Stimulation of osteoblastic differentiation and inhibition of interleukin-6 and nitric oxide in MC3T3-E1 cells by pomegranate ethanol extract. Phytother Res 2009; 23(5): 737-9
62. Monsefi M, Parvin F, Talaei-Khozani T. Effects of pomegranate extracts on cartilage, bone and mesenchymal cells of mouse fetuses. Brit J Nutr 2012; 107(5): 683-90
63. Rasheed Z, Akhtar N, Haqqi TM. Pomegranate extract inhibits the interleukin-1-induced activation of MKK-3, p38-MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. Arthritis Ther 2010; 12R: 195
64. Balbir-Gurman A, Fuhrman B, Braun-Moscovici Y, Markovits D, Aviram M. Consumption of pomegranate decreases serum oxidative stress and reduces disease activity in patients with active rheumatoid arthritis: a pilot study. Israel Med Assoc J 2011; 13(8): 474-9
65. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys Res Comm 2001; 288: 275-279.
66. Maggio D, Barabani M, Pierandrei M, et al. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a crosssectional study. J Clin Endocrinol Metab 2003; 88: 1523-7.
67. Sontakke AN, Tare RS. A duality in the roles of reactive oxygen species with respect to bone metabolism. Clin Chim Acta 2002; 318: 145-8.
68. Shuid AN, Ping LL, Muhammad N, Mohamed N, Soelaiman IN. The effects of Labisia Pumila var alata on bone markers and bone calcium in a rat model of post-menopausal osteoporosis. J Ethnopharm 2011;133: 538-42
69. Estai MA, Suhaimi FH, Das S, et al. Piper sarmentosum enhances fracture healing in ovariectomised osteoporotic rats: radiological study. Clinics 2011; 66(5): 865-72
70. Shuid AN, Abu Bakar MF, Abdul Shukor TA, et al. The AntiOsteoporotic Effect of Eurycoma Longifolia in Aged Orchidectomised Rat Model. Aging Male 2011; 14(3): 150-4
71. Aktifanus AT, Shuid AN, Rashid NHA, et al. Comparison of the Effects of Tocotrienol and Estrogen on the Bone Markers and Dynamic Changes in Postmenopausal Osteoporosis Rat Model. Asian J Anim Vet Adv 2012: 7: 225-34
72. Shuid AN, Loh H., Mohamed N, et al. Recycled Palm Oil Is Better Than Soy Oil in Maintaining Bone Properties in Menopausal Syndrome Model of Ovariectomized Rat. Asia Pac J Clin Nut 2007; 16(3): 393-402.
73. Shuid AN, Mohamed N, Muhammad N, Soelaiman IN. The Antiinflammatory Role of Vitamin E in Prevention of Osteoporosis. Adv Pharmacol Sci 2012; 2012: 142702.
74. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intimamedia thickness, blood pressure and LDL oxidation. Clin Nutr 2004; 23: 423-33.
75. Rosenblat M, Volkova N, Coleman R, Aviram M. Pomegranate byproduct administration to apolipoprotein e-deficient mice attenuates atherosclerosis development as a result of decreased macrophage oxidative stress and reduced cellular uptake of oxidized lowdensity lipoprotein. J Agr Food Chem 2006; 54: 1928-35.
76. Aviram M, Volkova N, Coleman R, et al. Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro in cultured macrophages and lipoproteins. J Agr Food Chem 2008; 56: 1148-56
77. Yoon JH, Baek SJ. Molecular Targets of Dietary Polyphenols with Anti-inflammatory Properties. Yonsei Med J 2005; 46(5): 585-96
78. Pacifici R, Rifas L, McCracken R, Avioli LV. The role of interleukin-1 in postmenopausal bone loss. Exp Gerontol 1990; 25(3-4): 309-16.
79. Khosla S, Peterson JM, Egan K, Jones JD, Riggs BL. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab 1994; 79(3): 707-11.
80. Hermizi H, Faizah O, Ima-Nirwana S, Shuid AN, Luke DA, Norazlina M. Negative effects of nicotine on bone resorbing cytokines and bone histomorphometric parameters in male rats. Jour Bone Min Metab 2007; 25: 93-98
81. Lee B, Thirunavukkarasu K, Zhou L, et al. Missense mutation abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 1997; 16: 307-10.
82. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblast. Cell 1997; 89: 755-64.
83. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-71
84. Nakajima D, Kim CS, Oh TW, et al. Suppressive effects of genistein dosage and resistance exercise on bone loss in ovariectomized rats. J Physiol Anthropol Appl Human Sci 2001; 20: 285-91.
85. Ishimi Y, Arai N, Wang X, et al. Difference in effective dosage of genistein on bone and uterus in ovariectomized mice. Biochem Biophys Res Commun 2000; 274: 697-701.
86. Ishida H, Uesugi T, Hirai K, et al. Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet. Biol Pharm Bull 1998; 21: 62-6.
87. Picherit C, Coxam V, Bennetau-Pelissero C, et al. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 2000; 130: 1675-81.
88. Tsuchida K, Mizushima S, Toba M, Soda K. Dietary soybeans intake and bone mineral density among 995 middle-aged women in Yokohama. J Epidemiol 1999; 9: 14-9.
89. Chiechi LM, Secreto G, D'Amore M, et al. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: The Menfis randomized trial. Maturitas 2002; 42: 295-300.
90. Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 2001; 8: 384-92.
91. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001; 86(5): 2032-42.
92. Sugiyama T. Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J Bone Miner Metab 2001; 19: 89-96